- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
First generic capecitabine approved for colorectal and breast cancers
FDA has approved the oral chemotherapy tablet capecitabine, the first generic version of Teva’s Xeloda, to treat cancer of the colon or rectum that has spread to other parts of the body. It also approved generic capecitabine for treatment of metastatic breast cancer.
FDA has approved the oral chemotherapy tablet capecitabine, the first generic version of Teva’s Xeloda, to treat cancer of the colon or rectum that has spread to other parts of the body. It also approved generic capecitabine for treatment of metastatic breast cancer.
Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150- and 500-mg strengths.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
